Navigation Links
Curemark CEO To Deliver Keynote Address at the BioScience Vision Summit
Date:9/16/2013

RYE, N.Y., Sept. 16, 2013 /PRNewswire/ -- Curemark LLC announced that CEO Dr. Joan Fallon will deliver the keynote at BioForward's BioScience Vision Summit in Madison, WI on September 18.  Life science entrepreneurs from across the country will attend the event, which focuses on biotechnology partnerships and innovation.

Dr. Fallon's address, "Growth by Association: Winning through Public and Private Partnerships," will highlight the clear benefits of the collaboration of government and business with life sciences stakeholders. Dr. Fallon's Wisconsin speech comes on the heels of her speech to the White House Office of Technology and Science, attended by senior Obama Administration officials.  

Dr. Fallon stated that, "I'm delighted and honored to be asked to deliver the keynote address at such an important conference and looking forward to meeting thought leaders from across the life sciences sector."

"Wisconsin is a center of innovation for the biosciences, which is why this conference is extremely important. Patients want help, particularly for the large number of still-unmet medical needs.  We need novel solutions and new thinking to move biotechnology forward," Dr. Fallon continued.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about our innovative science, visit www.curemark.com

Safe-Harbor Statements

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Curemark Enters into Research Collaboration with The Molecular Sciences Institute (VTT/MSI)
2. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
3. Cardiovascular Drug Delivery - Technologies, Markets and Companies - Updated 2012 Report
4. PI USA Offers High-End Compact Rotation Stage; Delivers High Performance and Precision via Air Bearings and Torque Motor
5. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
6. Biotech & BioPharma Professionals: CA Board of Pharmacy Executive, Virginia Herold, to Deliver Keynote at BSMA Annual Biotechnology Conference Oct 8-9
7. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
8. PolyScience Performance Programmable Circulating Baths Deliver Ultra-Precise, Highly Customizable Performance
9. Bend Research Presents Drug Delivery Advancements at Controlled Release Society Annual Meeting
10. Vaginal Ring Provides “Radically New” Drug Delivery Platform for Health Issues, Including Infertility
11. Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):